Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.42NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.19NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GR.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.568NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.13 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.372NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.634NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.37.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.630NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.360NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.578NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.544NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.448NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.425NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.354NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.1.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.3.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDDNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.60NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.6.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.2 (Zeta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
N.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.499NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
N.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.212NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.61NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.86NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.41.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.4.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JF.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JG.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBBNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.62NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GW.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.119.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.121 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.14 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used